Internal Medicine, Hematology & Oncology · Toms River, NJ
NPI
1053345629
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
40 Bey Lea Rd, Suite B 102
Toms River, NJ, 08753
Phone (732) 244-3380
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.2M
358,974 services
Medicare patients, 2024
952
Average age 78
Drug cost, 2024
$8.7M
1,525 prescriptions
Company payments, 2025
$1,425
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Chirag M Shah was code J1439 (injection, ferric carboxymaltose, 1 mg), 121,500 times for 69 patients. In total Chirag M Shah billed 358,974 services in 111 codes, and Medicare paid $4.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-03-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 121,500 | 69 | $0.87 | $106K |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 44,520 | 18 | $0.21 | $9,523 |
| J0897 Injection, denosumab, 1 mg | Office | 23,640 | 58 | $20.14 | $476K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 12,300 | 18 | $0.12 | $1,432 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 11,600 | 14 | $44.92 | $521K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 10,360 | 11 | $6.46 | $67K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 4,856 | 46 | $0.07 | $355 |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 3,980 | 18 | $5.77 | $23K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,834 | 52 | $0.09 | $341 |
| 99214 Office E&M - Established | Office | 1,255 | 531 | $108.92 | $137K |
| 96367 Intravenous Infusion, Hydration | Office | 934 | 60 | $25.94 | $24K |
| 99232 Hospital E&M - Subsequent | Facility | 870 | 247 | $69.96 | $61K |
| 99213 Office E&M - Established | Office | 733 | 427 | $73.68 | $54K |
| 96372 Injection Administration | Office | 688 | 90 | $12.63 | $8,689 |
| Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 624 | 19 | $114.72 | $72K |
By year: 2022 $3.9M for 301,711 services; 2023 $4.7M for 381,459 services; 2024 $4.2M for 358,974 services.
Medicare prescription drug claims, 2024
In 2024, the drug Chirag M Shah prescribed most often to Medicare patients was Anastrozole, with 159 prescriptions and refills. In total Chirag M Shah wrote 1,525 Medicare prescriptions that cost $8.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 159 | 454 | 58 | $4,293 |
| Hydroxyurea Generic | 82 | 198 | 22 | $2,730 |
| Ibrance Palbociclib | 78 | 78 | Under 11 | $1.2M |
| Erleada Apalutamide | 76 | 78 | Under 11 | $1.1M |
| Letrozole Generic | 64 | 176 | 21 | $1,805 |
| Prednisone Generic | 61 | 74 | 26 | $548 |
| Calquence Acalabrutinib Maleate | 56 | 56 | Under 11 | $755K |
| Imbruvica Ibrutinib | 44 | 44 | Under 11 | $482K |
| Zarxio Filgrastim-Sndz | 39 | 39 | Under 11 | $56K |
| Abiraterone Acetate Generic | 36 | 36 | Under 11 | $62K |
| Tagrisso Osimertinib Mesylate | 35 | 35 | Under 11 | $577K |
| Udenyca Autoinjector Pegfilgrastim-Cbqv | 35 | 35 | Under 11 | $144K |
| Pantoprazole Sodium Generic | 34 | 50 | 11 | $490 |
| Lenalidomide Generic | 32 | 32 | Under 11 | $413K |
| Jakafi Ruxolitinib Phosphate | 31 | 31 | Under 11 | $540K |
Brand drugs: 710 claims; generic drugs: 815 claims; opioid claims: 23.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Chirag M Shah $1,425 ($1,425 in general payments such as food, travel and fees) from 24 companies. The largest payer was Gilead Sciences, Inc. with $190.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 7 | $190 |
| Abbvie Inc. ABBV | 4 | $163 |
| Abbott Laboratories ABT | 1 | $160 |
| Janssen Biotech, Inc. JNJ | 2 | $134 |
| E.R. Squibb & Sons, L.L.C. BMY | 7 | $116 |
| Seagen Inc. PFE | 1 | $99.99 |
| Daiichi Sankyo Inc. 4568.T | 3 | $60.66 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $57.37 |
| Array Biopharma Inc PFE | 4 | $52.15 |
| Pfizer Inc. PFE | 3 | $50.84 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.